[Federal Register Volume 89, Number 188 (Friday, September 27, 2024)]
[Notices]
[Page 79300]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22137]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Chemical Probes and Drugs for Modulating HIV 
Transcription in the Context of Substance Use Disorders.
    Date: October 21, 2024.
    Time: 1:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Meysam Yazdankhah, M.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 402-6965, 
<a href="/cdn-cgi/l/email-protection#630e061a10020e4d1a021907020d080b020b230d0a0b4d040c15"><span class="__cf_email__" data-cfemail="caa7afb3b9aba7e4b3abb0aeaba4a1a2aba28aa4a3a2e4ada5bc">[email protected]</span></a>.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Mechanistic Research on Neuromodulation for SUD 
Treatment + Using Neuromodulation to Characterize the Continuum of 
Pathophysiology Between Substance Use and Mental Health.
    Date: November 18, 2024.
    Time: 11 a.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 827-4471, 
<a href="/cdn-cgi/l/email-protection#6e1c0f030f0a0f00071c2e030f07024000070640090118"><span class="__cf_email__" data-cfemail="d1a3b0bcb0b5b0bfb8a391bcb0b8bdffbfb8b9ffb6bea7">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: September 23, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-22137 Filed 9-26-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>